Market Closed -
OTC Markets
13:28:14 2024-06-17 EDT
|
5-day change
|
1st Jan Change
|
1.5
USD
|
+48.51%
|
|
0.00%
|
-36.40%
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2.068
|
0.66
|
0.2195
|
130.2
|
32.71
|
6.329
|
Enterprise Value (EV)
1 |
3.492
|
2.799
|
2.824
|
133.1
|
33.93
|
6.964
|
P/E ratio
|
-0.38
x
|
-0.87
x
|
0.12
x
|
-13.5
x
|
13.7
x
|
6.24
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
20.7
x
|
6
x
|
2
x
|
761
x
|
139
x
|
26.8
x
|
EV / Revenue
|
34.9
x
|
25.4
x
|
25.7
x
|
777
x
|
144
x
|
29.4
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
1.62
x
|
3.6
x
|
-0.68
x
|
23
x
|
-8.4
x
|
-3.15
x
|
FCF Yield
|
61.7%
|
27.8%
|
-147%
|
4.35%
|
-11.9%
|
-31.8%
|
Price to Book
|
-0.23
x
|
-0.06
x
|
-0.07
x
|
-9.78
x
|
-4.05
x
|
-1.24
x
|
Nbr of stocks (in thousands)
|
117
|
400
|
488
|
2,852
|
3,354
|
3,506
|
Reference price
2 |
17.70
|
1.650
|
0.4500
|
45.65
|
9.750
|
1.805
|
Announcement Date
|
12/27/18
|
6/21/21
|
8/4/21
|
12/22/21
|
11/15/22
|
11/20/23
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.1
|
0.11
|
0.11
|
0.1712
|
0.2355
|
0.2366
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1.426
|
-0.8749
|
-0.2093
|
-0.2008
|
-0.3396
|
-0.6869
|
Operating Margin
|
-1,425.78%
|
-795.37%
|
-190.29%
|
-117.28%
|
-144.2%
|
-290.39%
|
Earnings before Tax (EBT)
1 |
-4.715
|
-2.623
|
3.414
|
-6.765
|
2.444
|
1.157
|
Net income
1 |
-4.715
|
-2.623
|
3.414
|
-6.765
|
2.444
|
1.157
|
Net margin
|
-4,715.2%
|
-2,384.71%
|
3,104.02%
|
-3,951.79%
|
1,037.52%
|
488.89%
|
EPS
2 |
-46.50
|
-1.900
|
3.633
|
-3.370
|
0.7102
|
0.2894
|
Free Cash Flow
1 |
2.156
|
0.777
|
-4.146
|
5.794
|
-4.039
|
-2.212
|
FCF margin
|
2,156.34%
|
706.33%
|
-3,769.44%
|
3,384.61%
|
-1,714.96%
|
-934.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/27/18
|
6/21/21
|
8/4/21
|
12/22/21
|
11/15/22
|
11/20/23
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1.42
|
2.14
|
2.6
|
2.86
|
1.22
|
0.64
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2.16
|
0.78
|
-4.15
|
5.79
|
-4.04
|
-2.21
|
ROE (net income / shareholders' equity)
|
65.6%
|
26.2%
|
-37.4%
|
65%
|
-22.7%
|
-17.6%
|
ROA (Net income/ Total Assets)
|
-155%
|
-355%
|
-118%
|
-18.8%
|
-24%
|
-94.1%
|
Assets
1 |
3.051
|
0.739
|
-2.901
|
36
|
-10.19
|
-1.229
|
Book Value Per Share
2 |
-76.00
|
-27.40
|
-6.890
|
-4.670
|
-2.410
|
-1.460
|
Cash Flow per Share
2 |
0.0700
|
0.0200
|
-
|
0.2500
|
0.0200
|
0.0300
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/27/18
|
6/21/21
|
8/4/21
|
12/22/21
|
11/15/22
|
11/20/23
|
|
1st Jan change
|
Capi.
|
---|
| +16.49% | 122B | | +21.73% | 116B | | +22.18% | 27.03B | | -21.81% | 20.36B | | -16.89% | 16.43B | | -18.81% | 15.91B | | -44.74% | 15.6B | | +62.72% | 14.94B | | +3.09% | 13.59B |
Bio Therapeutic Drugs
|